Results 91 to 100 of about 31,287 (242)

Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis [PDF]

Rituximab was first used as a treatment for B-cell malign lymphoma, and it is currently used in the treatment of rheumatoid arthritis. On the other hand, an association between rheumatoid arthritis with another autoimmune disease Hashimoto’s thyroiditis ...
Hüseyin Demirci, Bilge Ceydilek, Ebru Aydoğan   +2 more
core   +1 more source

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis [PDF]

, 2009
Joseph M Tuscano1,2, Jacob Sands1,21Hematology and Oncology, Veterans Affairs, Northern California Health Care System, California, USA; 2Division of Hematology and Oncology, University of California, Davis School of Medicine, Sacramento, California ...
Joseph M Tuscano, Sands, Jacob, Jacob Sands, Tuscano, Joseph M   +3 more
core   +1 more source

Mucocutaneous Disease Activity and Damage Accrual in Systemic Lupus Erythematosus: Analyses From the Asia‐Pacific Lupus Collaboration Longitudinal Cohort Study

Arthritis Care &Research, EarlyView.
Objective This research article aims to describe the prevalence, associations, and health‐related quality of life (HRQoL) impact of mucocutaneous features of systemic lupus erythematosus (SLE). Methods Data from the Asia‐Pacific Lupus Collaboration cohort were analyzed (2013–2021).
Amanda M. Saracino, Yanjie Hao, Dylan Hansen, Yi‐Hsing Chen, Alberta Hoi, Vera Golder, Jiacai Cho, Aisha Lateef, Worawit Louthrenoo, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, Sandra Navarra, Leonid Zamora, Chak Sing Lau, Shirley Chan, Zhanguo Li, Hai‐hong Yao, Sargunan Sockalingam, B. M. D. B. Basnayake, Yasuhiro Katsumata, Masayoshi Harigai, Zhuoli Zhang, Jun Kikuchi, Yuko Kaneko, Tsutomu Takeuchi, Madelynn Chan, Sang‐Cheol Bae, Fiona Goldblatt, Sean O'Neill, Geraldine Hassett, Kristine Ng, Nicola Tugnet, Mark Sapsford, Yih Jia Poh, Michael Tee, Cherica Tee, Naoaki Ohkubo, Yoshiya Tanaka, Rangi Kandane‐Rathnayake, Eric Morand, Shereen Oon, Mandana Nikpour   +42 more
wiley   +1 more source

Rituximab for refractory granulomatous eye disease

, 2012
Elyse E Lower1,2 Robert P Baughman,1 Adam H Kaufman31Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA; 2Oncology Hematology Care, Cincinnati, OH, USA; 3Department of Ophthalmology, University of Cincinnati, Cincinnati,
Baughman RP, Kaufman AH, Lower EE
core  

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma [PDF]

, 2011
PURPOSE: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations.
Rossi, F G, Lugtenburg, P.J. (Pieternella), Pieternella J. Lugtenburg, Ulrich Dührsen, Bendall, K. (Kate), Dührsen, U. (Ulrich), Silvestre, AS, Francesca G. Rossi, Jaeger, U, Jaeger, Ulrich, Gaia Rossi, F. (Francesca), Matthias Schwenkglenks, Pettengell, R, Schwenkglenks, Matthias, Rossi, FG, Salar Silvestre, A, Dührsen, U, Szabo, C. (Csilla), Johnson, Hans E., Dührsen, Ulrich, Schwenkglenks, M, Bendall, Kate, Lugtenburg, PJ, Rossi, Francesca G, Hans E. Johnson, Rossi, Francesca G., Bendall, K, Jaeger, U. (Ulrich), Szabo, Z, Johnsen, HE, Silvestre, Antonio Salar, Johnson, H.E. (Hans), Pettengell, Ruth, Lugtenburg, Pieternella J., Lugtenburg, Pieternella J, Zsolt Szabo, Ruth Pettengell, Johnsen, Hans E, Szabo, Zsolt, Silvestre, J.S. (Jean Sebastien), Schwenkglenks, M. (Matthias), Pettengell, R. (Ruth), Antonio Salar Silvestre, Ulrich Jaeger, Johnson, H E, Lugtenburg, P J, Kate Bendall   +46 more
core   +1 more source

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up

Arthritis Care &Research, EarlyView.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker, Yangyuna Yang, Punyasha Roul, Aaron Baraff, Myra S. Schmaderer, Lani Zimmerman, Kaleb Michaud, Namrata Singh, Grant W. Cannon, Gary Kunkel, Ted R. Mikuls, Ariela R. Orkaby, Joshua F. Baker, Bryant R. England, Katherine D. Wysham   +14 more
wiley   +1 more source

Real-world outcomes with rituximab vs. conventional therapy in pemphigus vulgaris: a single-center Romanian cohort

Frontiers in Medicine
BackgroundPemphigus vulgaris (PV) is a rare but potentially life-threatening autoimmune blistering disease. Rituximab has recently gained prominence as a first-line treatment for moderate-to-severe PV, yet real-world evidence from Eastern Europe remains ...
Daciana Elena Brănișteanu, Torello Lotti, Cristina Colac Boțoc, Antonia Elena Huțanu, Cătălina Anca Munteanu, Roxana Paraschiva Ciobanu, Daniel Constantin Brănișteanu, Alin Gabriel Colac, Cătălina Ioana Onu Brănișteanu, George Brănișteanu, Ștefan Vasile Toader, Mihaela Paula Toader   +11 more
doaj   +1 more source

Update on the use of rituximab for intractable rheumatoid arthritis

, 2009
R John LooneyUniversity of Rochester, Rochester, New York, USAAbstract: It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate ...
R John Looney
core  

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis

, 2017
Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients.
Nur Kebapçı, Nilgün Yıldırım, Belgin Efe, Tülay Şimşek   +3 more
core   +1 more source

Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis

Arthritis Care &Research, EarlyView.
Objective Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long‐term predictors remain inadequately studied, requiring long‐term follow‐up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort.
Shangzhu Zhang, Laurence Magder, Daniel Goldman, Judith A. James, Joel M. Guthridge, Carla Guthridge, Peter Izmirly, Jill P. Buyon, H. Michael Belmont, Richard A. Furie, Noa Schwartz, Chaim Putterman, Jennifer L. Barnas, Jennifer H. Anolik, Sarah French, Maria Dall'Era, Avi Z. Rosenberg, Jeffrey Hodgin, Dawit S. Demeke, the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) Network, Michelle Petri, Andrea Fava   +21 more
wiley   +1 more source